Area of research
Surgery · Cancer Research
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Cancer, Hypoxia, and Metabolism, Renal cell carcinoma treatment, and Epigenetics and DNA Methylation.
FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression
ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).
Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study